Neurological disorders news - the latest biotech news

Home Neurological disorders Page 14

Latest Posts

mimetas organ on chip

News and Trends 22 Dec 2015

Dutch Organ-on-Chip Biotech Hauls in €1.5M Funding from Pharma Syndicate in Project Against Animal Testing

Mimetas from Leiden (NL) has now been financed to develop an Organ-on-Chip (tissue model) to specifically test Neurotoxicity, as a piece of medtech to help clinical trials move away from Animal testing… Organs-on-Chips are microfluidic tissue models which mimic basic organ-to-organ coupling. Developed with the aim of simulating ADMET testing and drug screening in vitro, […]

December 22, 2015 - 3 minutesmins - By Dani Bancroft

probiodrug small molecule alzheimers disease trial

News and Trends 15 Dec 2015

Latest Small Molecule against Alzheimer’s Disease Success in Phase I Trials

Probiodrug‘s phase I tolerability and efficacy trial for Alzheimer’s didn’t quite go as planned, although results are in and it is still good news for this small molecule candidate. Probiodrug in Halle (Germany) is pioneering immunotherapy approaches to eliminate pyroglutamated (pGlu) Abeta, a highly toxic peptide that has been linked to the progression of Alzheimer’s […]

December 15, 2015 - 3 minutesmins - By Dani Bancroft

hydra

News and Trends 7 Dec 2015

Hydra’s Immortality is not Myth: Polyps Genetically Reprogram Skin Cells into Neurons

Relatives of the Jellyfish, researchers at the University of Geneva (Switzerland) have now proven the regenerative abilities of Hydra involved reprogramming cells. Does this have any implications for Neurodegenerative disease? Remember the Greek myth of Hydra? Amongst other twelve labours, Hercules had to slay the nine-headed monster Hydra which, in case nine jaws weren’t enough, […]

December 7, 2015 - 3 minutesmins - By Lourdes Riquelme

cytotools medday stock black friday drop phase III fail

News and Trends 4 Dec 2015

Black Friday Ruin as TWO Biotechs Fail in Phase III Trials

A shocking Black Friday for these two Biotechs: Both CytoTools (Germany) and MedDay (France) phase III trials in chronic disease flopped massively, and stocks dropped as much as 85% in one day… Multiple Sclerosis Headliner, MedDay’s MD1003, has flopped in its phase III trial after failing to meet its primary endpoint. This is a disastrous […]

December 4, 2015 - 3 minutesmins - By Dani Bancroft

heptares pfizer gcpr sosei

News and Trends 30 Nov 2015

Heptares’ G-Protein StaR Platform has now Hooked Pfizer in a Billion Euro Deal

Heptares Therapeutics from the UK has landed Pfizer in a huge potential $1.9Bn deal for their G-protein receptor platform. Heptares Therapeutics was founded by Fiona Marshall (one of our Top 10 UK Women in Biotech), who now serves as a CSO to Japanese Big boss Sosei, which wholly acquired Heptares earlier this year in a […]

November 30, 2015 - 2 minutesmins - By Dani Bancroft

teva heptares migraine GPCR

News and Trends 26 Nov 2015

The UK-Israeli €378M Small-Molecule Offensive Against Migraines

The Israeli TEVA and UK Heptares Therapeutics (now owned by Japanese Sosei) have partnered up on novel drug therapies targeting Migraines. The pain and disruption migraines can cause pain that lasts from 4 to 72 hours, and around 10 million worldwide suffer such episodes on a regular basis. Signs and symptoms of a migraine include photosensitivity […]

November 26, 2015 - 2 minutesmins - By Dani Bancroft

ADVERTISEMENT

Alzheimers

News and Trends 24 Nov 2015

2015 Review: What Exciting Developments Have Been Made in Neurodegenerative Disease?

Since both Alzheimer’s Disease and Parkinson’s combined affect up to 50 million people worldwide, it is no wonder this new wave of break-through milestones is getting the industry excited… The Central Nervous System (CNS) comprises many complex tissues and highly specialized cell types, mutation in which can cause an array of deadly and chronic diseases. […]

November 24, 2015 - 9 minutesmins - By Dani Bancroft

Proteros epigenetics 2

News and Trends 17 Nov 2015

Epigenetics Drug Discovery has a New Champion!

Last week at BIO-Europe 2015 in Munich, I had the opportunity to meet Torsten Hoffmann, CSO of Proteros who told me more about the recent incursion of his company in the Epigenetics space! Proteros is a leader of the Structural Biology field. So, what is this field exactly? Usually, when a Pharmaceutical company is looking […]

November 17, 2015 - 4 minutesmins - By Joachim Eeckhout

swissmedic newron xadago zambon parkinsons

News and Trends 16 Nov 2015

Swissmedic Approves Zambon and Newron Therapy against Parkinson’s

Italian Pharma Newron and its partner Zambon (from Milan) have been granted a license by Swissmedic (the regulatory agency in Switzerland) for Xadago, a new combo ‘add-on’ therapy for Parkinson’s Disease. Zambon, is a Pharmaceutical Company with a strong commitment in central nervous system (CNS) diseases. Its partner, Newron Pharmaceuticals, is a research and development biotech from northern […]

November 16, 2015 - 2 minutesmins - By Julie Lellouche

Dementia discovery fund

News and Trends 26 Oct 2015

Dementia could bankrupt us all… The Biotech ‘A’ Team comes to the rescue!

The fight against Alzheimer‘s with the World Health Organization and the G8 Dementia Summit rallies a collective of biotech industry specialists also wanting in on the battle front. The latest development in the Dementia Discovery Fund (DDF) includes US Biogen‘s dramatic cuts to redirect $250M into the Neurodegenerative disease venture, and investment into $100M ‘A’ […]

October 26, 2015 - 3 minutesmins - By Dani Bancroft

Neurodegenerative disease

News and Trends 15 Oct 2015

Neurodegenerative Disease in the UK: Takeda, NIHR & UCL Research Collaboration

Takeda Cambridge (the UK subsidiary of global biotech Takeda Pharmaceuticals) will now collaborate with University College London‘s Institute for Neurology and their NHS teaching hospital to search for novel gene targets with significance in neurodegenerative disease. Takeda has already got massive Alzheimer‘s clout in the industry for its blockbuster Galantamine Hydrobromide (branded REMINYL in Japan), […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

YSIOS

News and Trends 15 Oct 2015

Spanish connection: VC leads Biotech series A Fund to cure Rare Neurodegenerative Disease

Minoryx Therapeutics is a Barcelona based Rare-disease specialist who has a panel of orphan-drug experts for their discovery program. Now backed in a €19.4M Series A round from leading VC firms Ysios (No 15 in our top EU VCs) and Roche Venture Fund, Minoryx will have the well-needed cash to push for further R&D of their […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

ADVERTISEMENT